| 摘要 |
1. A composition comprising (S)-2-(benzylamino-methyl)-2,3,8,9-tetrhydro-7H-1,4-dioxino [2,3-e] indol-8-one and an antipsychotic agent. 2. A pharmaceutical composition comprising (S)-2-(benzylaminomethyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino [2,3-e] indol-8-one, an antipsychotic agent, and one or more pharmaceutical carriers therefor. 3. A pharmaceutical composition for treating a patient suffering from a psychotic disorder comprising an effective amount of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino [2,3-e] indol-8-one, in combination with an effective amount of an antipsychotic agent. 4. A composition according to any one of Claims 1 to 3 wherein the antipsychotic agent is an atypical antipsychotic. 5. A composition according to any one of Claims 1 to 3 wherein the antipsychotic agent is a typical antipsychotic. 6. A composition according to any one of Claims 1 to 3 wherein the antipsychotic agent is selected from chlorpromazine, mesoridazine, thioridazine, fluphenazine, trifluoperazine, perphenazine, clozapine, haloperidol, loxapine, molindone, thiothixene, risperidone, seroquel, and olanzapine. 7. A composition according to any one of Claims 1 to 6 wherein the composition is adapted for oral administration. 8. A composition according to any one of Claims 1 to 7 wherein the composition is adapted to administer the antipsychotic in the amount of about 10 mg to about 1000 mg per day. 9. A method of treating a patient suffering from a psychotic disorder comprising administering to said patient an effective amount of (S)-2-(benzylaminomethyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino [2,3-e] indol-8-one, in combination with an effective amount of an antipsychotic agent. 10. The method of Claim 9 wherein the antipsychotic agent is an atypical antipsychotic. 11. The method of Claim 9 wherein the antipsychotic agent is a typical antipsychotic. 12. The method of Claim 9 wherein the antipsychotic agent is selected from the group consisting of chlorpromazine, mesoridazine, thioridazine, fluphenazine, trifluoperazine, perphenazine, clozapine, haloperidol, loxapine, molindone, thiothixene, risperidone, seroquel, and olanzapine. 13. The method of any one of Claims 9 to 12 wherein administration of the compounds is oral. 14. The method of Claim 9 wherein the patient is suffering from schizophrenia. 15. The method of Claim 9 wherein the patient is suffering from schizoaffective disorder. 16. The method of Claim 9 wherein the patient is suffering from depression. 17. The method of Claim 9 wherein the antipsychotic is administered in the amount of about 10 mg to about 1000 mg per day. 18. A product comprising (S)-2-(benzylaminomethyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino [2,3-e] indol-8-one and an antipsychotic agent as a combined preparation for simultaneous, separate or sequential administration to treat a patient suffering from a psychotic disorder. 19. A product according to Claim 18 wherein the antipsychotic agent is an atypical antipsychotic. 20. A product according to Claim 18 wherein the antipsychotic agent is a typical antipsychotic. 21. A product according to Claim 18 wherein the antipsychotic agent is selected from chlorpromazine, mesoridazine, thioridazine, fluphenazine, trifluoperazine, perphenazine, clozapine, haloperidol, loxapine, molindone, thiothixene, risperidone, seroquel, and olanzapine. 22. A product according to any one of Claims 18 to 21 which is adapted for oral administration. 23. A product according to Claim 18 for treating schizophrenia. 24. A product according to Claim 18 for treating schizoaffective disorder. 25. A product according to Claim 18 for treating depression. 26. A patient pack comprising at least one active ingredient selected from (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino [2,3-e] indol-8-one and an antipsychotic agent, and comprising an information insert containing directions on the use of the active ingredient or active ingredients in a combination comprising (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino [2,3-e] indol-8-one and an antipsychotic agent. |
